Compare Stocks: TELO, FHTX, ALEC, and BCYC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.27 -8.1%	$1.92	$1.09 ▼ $3.40	$253.46M	0.65	880,299 shs	505,604 shs
BCYC Bicycle Therapeutics	$4.01 -4.1%	$4.16	$3.74 ▼ $9.16	$280.66M	1.54	404,871 shs	399,469 shs
FHTX Foghorn Therapeutics	$4.67 -3.3%	$5.66	$3.27 ▼ $7.61	$277.33M	2.86	223,093 shs	198,253 shs
TELO Telomir Pharmaceuticals	$1.22 +2.1%	$1.17	$0.89 ▼ $2.09	$83.56M	-0.25	119,195 shs	32,062 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	+0.41%	+2.92%	+38.76%	+62.50%	-10.51%
BCYC Bicycle Therapeutics	-2.79%	+1.95%	+0.24%	+3.72%	-40.29%
FHTX Foghorn Therapeutics	-1.83%	-15.11%	-20.43%	+25.45%	-16.00%
TELO Telomir Pharmaceuticals	+2.59%	+8.18%	+2.59%	-4.03%	-3.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.27 -8.1%	$1.92	$1.09 ▼ $3.40	$253.46M	0.65	880,299 shs	505,604 shs
BCYC Bicycle Therapeutics	$4.01 -4.1%	$4.16	$3.74 ▼ $9.16	$280.66M	1.54	404,871 shs	399,469 shs
FHTX Foghorn Therapeutics	$4.67 -3.3%	$5.66	$3.27 ▼ $7.61	$277.33M	2.86	223,093 shs	198,253 shs
TELO Telomir Pharmaceuticals	$1.22 +2.1%	$1.17	$0.89 ▼ $2.09	$83.56M	-0.25	119,195 shs	32,062 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	+0.41%	+2.92%	+38.76%	+62.50%	-10.51%
BCYC Bicycle Therapeutics	-2.79%	+1.95%	+0.24%	+3.72%	-40.29%
FHTX Foghorn Therapeutics	-1.83%	-15.11%	-20.43%	+25.45%	-16.00%
TELO Telomir Pharmaceuticals	+2.59%	+8.18%	+2.59%	-4.03%	-3.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.13	Hold	$3.63	60.04% Upside
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	246.00% Upside
FHTX Foghorn Therapeutics	2.88	Moderate Buy	$11.43	144.99% Upside
TELO Telomir Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest TELO, FHTX, ALEC, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/30/2026	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
7/17/2026	FHTX Foghorn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TELO Telomir Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	BCYC Bicycle Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$13.86M	18.24	N/A	N/A	$0.28 per share	8.09
BCYC Bicycle Therapeutics	$72.86M	3.85	N/A	N/A	$8.79 per share	0.46
FHTX Foghorn Therapeutics	$36.74M	7.54	N/A	N/A	($1.92) per share	-2.43
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.10	N/A	N/A	N/A	-850.13%	-531.03%	-44.00%	11/5/2026 (Estimated)
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	11/4/2026 (Estimated)
TELO Telomir Pharmaceuticals	-$10.41M	-$0.91	N/A	N/A	N/A	N/A	-102.70%	-90.75%	N/A

Latest TELO, FHTX, ALEC, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.79	-$0.72	-$0.79	N/A	N/A
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.10 million
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.26	5.26
BCYC Bicycle Therapeutics	N/A	12.08	12.08
FHTX Foghorn Therapeutics	N/A	3.36	3.36
TELO Telomir Pharmaceuticals	N/A	16.16	16.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
BCYC Bicycle Therapeutics	86.15%
FHTX Foghorn Therapeutics	61.55%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
BCYC Bicycle Therapeutics	22.00%
FHTX Foghorn Therapeutics	9.02%
TELO Telomir Pharmaceuticals	16.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	111.66 million	102.39 million	Optionable
BCYC Bicycle Therapeutics	240	69.99 million	54.60 million	Optionable
FHTX Foghorn Therapeutics	120	59.39 million	54.03 million	Optionable
TELO Telomir Pharmaceuticals	1	68.78 million	57.52 million	N/A

TELO, FHTX, ALEC, and BCYC Headlines

Recent News About These Companies

Telomir Pharmaceuticals (TELO) to Post Quarterly Earnings on Wednesday

August 26, 2026 | marketbeat.com

Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results

August 13, 2026 | marketbeat.com

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?

August 12, 2026 | defenseworld.netD

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% - Should You Sell?

August 12, 2026 | marketbeat.com

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

August 10, 2026 | markets.businessinsider.com

Telomir-Zn Preclinical Data Support Advancement in TNBC

August 10, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models

August 10, 2026 | quiverquant.comQ

TELO Telomir Pharmaceuticals, Inc.

July 8, 2026 | seekingalpha.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...

June 15, 2026 | usatoday.com

Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data

June 15, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

June 15, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change

June 8, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral$

Telomir Pharmaceuticals Inc TELO

May 26, 2026 | morningstar.comM

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease

May 20, 2026 | usatoday.com

Telomir-Zn Preclinical Data Published in Wilson’s Disease

May 20, 2026 | tipranks.com

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

May 20, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn

April 30, 2026 | tipranks.com

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

April 30, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

April 24, 2026 | usatoday.com

Telomir Pharmaceuticals Inc.

April 2, 2026 | barrons.com

Telomir seeks FDA approval for Telomir-1 to treat breast cancer

April 2, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, FHTX, ALEC, and BCYC Company Descriptions

Alector NASDAQ:ALEC

$2.27 -0.20 (-8.10%)

Closing price 04:00 PM Eastern

Extended Trading

$2.28 +0.00 (+0.22%)

As of 04:10 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Bicycle Therapeutics NASDAQ:BCYC

$4.01 -0.17 (-4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$4.00 0.00 (-0.12%)

As of 05:05 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Foghorn Therapeutics NASDAQ:FHTX

$4.67 -0.16 (-3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$4.72 +0.05 (+0.99%)

As of 04:57 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Telomir Pharmaceuticals NASDAQ:TELO

$1.22 +0.03 (+2.10%)

Closing price 03:59 PM Eastern

Extended Trading

$1.18 -0.03 (-2.47%)

As of 04:42 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, FHTX, ALEC, and BCYC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, FHTX, ALEC, and BCYC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, FHTX, ALEC, and BCYC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, FHTX, ALEC, and BCYC Company Descriptions

Alector NASDAQ:ALEC

Bicycle Therapeutics NASDAQ:BCYC

Foghorn Therapeutics NASDAQ:FHTX

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, FHTX, ALEC, and BCYC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, FHTX, ALEC, and BCYC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, FHTX, ALEC, and BCYC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, FHTX, ALEC, and BCYC Company Descriptions

Alector NASDAQ:ALEC

Bicycle Therapeutics NASDAQ:BCYC

Foghorn Therapeutics NASDAQ:FHTX

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools